Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis —Variations in Real-World Experience—Reply

In Reply We thank Dr Wolf and colleagues for highlighting the importance of clinical context when evaluating effectiveness of multiple sclerosis (MS) therapies. As demonstrated in the comparative effectiveness of natalizumab and fingolimod, where seemingly discordant results emerged from different registries, characteristics of the study population play a central role in study findings. It is, therefore, important to differentiate between studies of treatment efficacy and effectiveness.
Source: JAMA Neurology - Category: Neurology Source Type: research